Literature DB >> 18068276

How much cervical cancer in Australia is vaccine preventable? A meta-analysis.

Julia M L Brotherton1.   

Abstract

This study aimed to estimate the proportion of cervical cancer attributable to high risk HPV types covered by the prophylactic HPV vaccines (HPV types 16 and 18) in Australia. By applying a systematic search strategy and established inclusion criteria, seven studies containing 553 cervical cancers were identified for inclusion. The most frequent types identified were HPV16 (60.4%), HPV18 (19.7%) and HPV45 (4.6%). Overall 80.1% (95%CI 72.7-87.8%) contained types 16 or 18. Removing 13 cancers with both types, an HPV16/18 vaccine could have prevented 77.7% of cervical cancers. This finding implies that Australia may have more to gain from the adoption of currently formulated HPV vaccines than other countries.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18068276     DOI: 10.1016/j.vaccine.2007.10.057

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  HPV catch-up vaccination of young women: a systematic review and meta-analysis.

Authors:  Elisabeth Couto; Ingvil Sæterdal; Lene Kristine Juvet; Marianne Klemp
Journal:  BMC Public Health       Date:  2014-08-23       Impact factor: 3.295

2.  Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy.

Authors:  Junyu Chen; Shuhua Zhao; Wenxi Tan; Taiwei Wang; Shan Wu; Changshuai Wang; Yu Jiang; Tuo Zhou; Zhuo Zhang; Lijing Zhao
Journal:  Sci Rep       Date:  2021-10-11       Impact factor: 4.379

3.  Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand.

Authors:  Leonardo M Simonella; Hazel Lewis; Megan Smith; Harold Neal; Collette Bromhead; Karen Canfell
Journal:  BMC Infect Dis       Date:  2013-03-03       Impact factor: 3.090

4.  Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study).

Authors:  Elisa J Young; Sepehr N Tabrizi; Julia Ml Brotherton; John D Wark; Jan Pyman; Marion Saville; C David Wrede; Yasmin Jayasinghe; Jeffrey Tan; Dorota M Gertig; Marian Pitts; Suzanne M Garland
Journal:  BMC Cancer       Date:  2013-06-19       Impact factor: 4.430

5.  Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data.

Authors:  Megan A Smith; Bette Liu; Peter McIntyre; Robert Menzies; Aditi Dey; Karen Canfell
Journal:  BMC Infect Dis       Date:  2016-02-01       Impact factor: 3.090

6.  Projected impact of HPV vaccination and primary HPV screening on cervical adenocarcinoma: Example from Australia.

Authors:  Megan A Smith; Karen Canfell
Journal:  Papillomavirus Res       Date:  2017-04-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.